Idenix Biopharmaceuticals

Idenix Biopharmaceuticals was a biopharmaceutical company specialized in the discovery and development of oral antiviral therapeutics for the treatment of human viral diseases. The company's primary focus was on chronic hepatitis C (HCV), hepatitis B (HBV), and HIV, utilizing its deep expertise in nucleoside and nucleotide chemistry. Idenix successfully brought telbivudine to market for HBV in partnership with Novartis before shifting its focus toward next-generation direct-acting antivirals for HCV. In 2014, the company was acquired by Merck & Co. for approximately $3.85 billion to strengthen Merck's position in the competitive hepatitis C market. The acquisition was driven by Idenix's promising pipeline of NS5B polymerase inhibitors and NS5A inhibitors.